Gilbert Mark R
Department of Neuro-oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Curr Oncol Rep. 2006 Jan;8(1):45-9. doi: 10.1007/s11912-006-0008-6.
The prognosis for patients with malignant primary brain tumors has been poor, and until recently, there was little evidence that chemotherapy was beneficial. The publication of the phase III trial comparing the combination of temozolomide with external beam radiation therapy with radiation therapy alone demonstrated a clear survival benefit for the combination regimen. These results, along with improvements in clinical trial design and outcome assessment, advances in our understanding of glioma tumor biology, and recognition of critical drug-drug interactions, have provided a foundation for developing better treatments for these cancers.
恶性原发性脑肿瘤患者的预后一直很差，直到最近，几乎没有证据表明化疗有益。一项三期试验比较了替莫唑胺与外照射放疗联合使用和单独放疗的效果，该试验的发表表明联合治疗方案具有明显的生存益处。这些结果，连同临床试验设计和结果评估的改进、我们对胶质瘤肿瘤生物学理解的进步以及对关键药物相互作用的认识，为开发针对这些癌症的更好治疗方法奠定了基础。
